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Effect of Ginkgo Biloba on the Pharmacokinetics of Raltegravir in
Healthy Volunteers
Maren Blonk,a,b Angela Colbers,a,b Anne Poirters,c Bas Schouwenberg,d and David Burgera,b
Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlandsa; Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Nijmegen, The
Netherlandsb; Biomedical Sciences, Radboud University Nijmegen, Nijmegen, The Netherlandsc; and Department of Pharmacology and Toxicology, Radboud University
Nijmegen Medical Centre, Nijmegen, The Netherlandsd
Medicinal herbs may cause clinically relevant drug interactions with antiretroviral agents. Ginkgo biloba extract is a popu-
lar herbal product among HIV-infected patients because of its positive effects on cognitive function. Raltegravir, an HIV
integrase inhibitor, is increasingly being used as part of combined antiretroviral therapy. Clinical data on the potential
inhibitory or inductive effect of ginkgo biloba on the pharmacokinetics of raltegravir were lacking, and concomitant use
was not recommended. We studied the effect of ginkgo biloba extract on the pharmacokinetics of raltegravir in an open-
label, randomized, two-period, crossover phase I trial in 18 healthy volunteers. Subjects were randomly assigned to a regi-
men of 120 mg of ginkgo biloba twice daily for 15 days plus a single dose of raltegravir (400 mg) on day 15, a washout pe-
riod, and 400 mg of raltegravir on day 36 or the test and reference treatments in reverse order. Pharmacokinetic sampling
of raltegravir was performed up to 12 h after intake on an empty stomach. All subjects (9 male) completed the trial, and no
serious adverse events were reported. Geometric mean ratios (90% confidence intervals) of the area under the plasma con-
centration-time curve from dosing to infinity (AUC0-) and the maximum plasma concentration (Cmax) of raltegravir with
ginkgo biloba versus raltegravir alone were 1.21 (0.93 to 1.58) and 1.44 (1.03 to 2.02). Ginkgo biloba did not reduce ralte-
gravir exposure. The potential increase in the Cmax of raltegravir is probably of minor importance, given the large inter-
subject variability of raltegravir pharmacokinetics and its reported safety profile.
Approximately 60% of HIV-infected patients use complemen-tary and alternativemedicines to treatHIV-related symptoms
and the side effects of conventional antiretroviral therapy. Herbal
medicines can cause clinically significant interactions with anti-
retroviral agents, with potential drug failure as a result (17, 26).
Among the most popular herbal products used worldwide is
ginkgo biloba extract, which is made from the leaves of the ginkgo
biloba tree. It is used for the treatment of peripheral vascular dis-
ease and is frequently taken for its claimed beneficial effects on
concentration, memory, depressive disorders, and dementia (1).
Because cognitive impairment is one of the most feared compli-
cations among HIV-infected patients, the popularity of ginkgo
biloba within this patient group is easily explained (23). Although
ginkgo biloba extract has potential beneficial effects, self-medica-
tion with ginkgo biloba may lead to undesirable drug interactions
with regular medication. For example, a study in healthy subjects
showed that plasma concentrations of midazolam (a CYP3A
probe) were significantly reduced after ginkgo biloba intake (22).
If this were also true with antiretroviral agents, it could place in-
dividual patients at risk for virological failure.
In past years, a few articles have been published about the po-
tential negative effects of ginkgo biloba on the pharmacokinetics
of antiretroviral agents. One case report described virological fail-
ure in an HIV-infected patient taking an efavirenz-based regimen
due to concomitant use of ginkgo biloba. Although the underlying
mechanism remained unclear, terpene lactones in ginkgo biloba
may lower plasma efavirenz levels by the induction of CYP2B6,
CYP3A4, and/or P-glycoprotein (P-gp) (28). Unlike the inductive
effects of ginkgo biloba on the pharmacokinetics of midazolam,
ginkgo biloba extract did not change the exposure of lopinavir (a
protease inhibitor and CYP3A substrate) when used with low-
dose ritonavir. The use of low-dose ritonavir, a potent CYP3A
inhibitor, may have offset the effect of ginkgo biloba on the phar-
macokinetics of lopinavir (22).
In vivo data on ginkgo biloba with other antiretroviral drug
classes, such as HIV integrase inhibitors, like raltegravir, are lack-
ing. According to current guidelines, raltegravir in combination
with tenofovir/emtricitabine is recommended as one of the pre-
ferred regimens for antiretroviral-naïve patients (8, 21). Raltegra-
vir targets the HIV-1 integrase enzyme and prevents the integra-
tion of viral DNA into the genome of the host cell. Raltegravir has
shown sustained antiretroviral activity, is generally well tolerated,
and has little propensity to interact with other drugs. The primary
route of metabolism is glucuronidation via UDP-glucuronyl-
transferase 1A1 (UGT1A1) in the liver, with minor contributions
from UGT1A3 and UGT1A9 (6, 12, 13). In vitro studies suggest
that raltegravir is a weak P-gp substrate (20). There is in vitro and
animal evidence that ginkgo biloba modulates UGT enzymes.
Ginkgo biloba extract and ginkgolides induce the expression of
UGT1A1 in human primary hepatocytes, although inhibitory ef-
fects on UGT enzymes of ginkgo biloba extract, or one of its com-
ponents, have been described, as well (16, 18, 19, 29). Other inves-
tigations showed that long-term use of ginkgo biloba inhibits
P-gp-mediated drug transport, but contrary results have also been
reported (1, 9, 10, 30, 31).
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Given the inconclusive data on the potential inhibitory or in-
ductive effect of ginkgo biloba extract on glucuronidation or P-
gp-mediated transport, ginkgo biloba may theoretically influence
the exposure to raltegravir. Therefore, concomitant use is cur-
rently not recommended. The objectives of this study were to
assess the effect of steady-state ginkgo biloba on the pharmaco-
kinetics of a single dose of raltegravir in healthy volunteers and to
evaluate the safety and tolerability of the combination.
MATERIALS AND METHODS
Study design. This open-label, randomized, two-period, crossover, sin-
gle-center, phase I trial was conducted from December 2010 to March
2011 at the Radboud University Nijmegen Medical Centre (Nijmegen,
The Netherlands). The study was designed to examine the effect of mul-
tiple doses of ginkgo biloba on the pharmacokinetics of a single dose of
raltegravir by intrasubject comparison. The secondary objective was to
evaluate the safety of the combined use of raltegravir and ginkgo biloba.
Eighteen healthy volunteers (9 females and 9 males) were stratified
according to gender in groups A and B. In group A, participants received
120 mg of ginkgo biloba twice daily for 14 days, followed by a single dose
on day 15, together with a single dose of 400 mg of raltegravir. After a
washout period of 3 weeks, the participants received a single dose of 400
mg of raltegravir on day 36. In group B, participants received the test and
reference treatments in reverse order. They received a single dose of 400
mg of raltegravir on day 15, followed by a washout period of 1 week. On
day 22, they started ginkgo biloba treatment (120 mg twice daily for 14
days). On day 36, participants took a single dose of ginkgo biloba together
with a single dose of 400 mg of raltegravir. The trial was approved by the
Investigational Review Board of the Radboud University Nijmegen Med-
ical Centre, Nijmegen, The Netherlands. The trial was conducted in ac-
cordance with good clinical practice and the Declaration of Helsinki. The
study was registered at http://www.ClinicalTrials.gov (NCT01246804).
Study population.Healthy male and female participants between the
ages of 18 and 55 years and with a body mass index of 18 to 30 kg/m2
(extremes included) were eligible for enrollment. The included partici-
pants had to be in good, age-appropriate health, as established by physical
examination, medical history, electrocardiography, and biochemical, he-
matologic, and urinalysis testing within 4 weeks prior to day 1. The sub-
jects had to be able and willing to sign an informed consent form prior to
screening evaluations. The main exclusion criteria were a history of sen-
sitivity or idiosyncrasy tomedicinal products or excipients, a positiveHIV
or hepatitis B or C test result, or therapy with any drug (for 2 weeks
preceding dosing), except for acetaminophen. Other exclusion criteria
were participation in a drug trial or blood donationwithin 60 days prior to
day 1 of the study. Pregnant and breastfeeding females were also excluded.
Study drug and dosing.Ginkgo biloba extract is a complexmixture of
chemical constituents, and the actual contentsmay vary depending on the
part of the plant being processed, the season, or the manufacturing pro-
cess (1). The industry standard for powdered extracts, as used in this
study, is 24% flavonoids (quercetin, kaempferol, and isorhamnetin,
among others) and 6% terpene lactones (ginkgolides and bilobalide) by
weight. In this trial, the commercial product Tavonin (a tablet with 40mg
of ginkgo biloba extract) was used because of its standardized composi-
tion of 9.6mg of flavonoids and 2.4mg of terpene lactone. Tavonin (Will-
mar SchwabeGmbH,Karlsruhe,Germany) is licensed inTheNetherlands
for the treatment of occlusive peripheral arterial disease. The ginkgo bi-
loba dose used in this trial (120 mg twice daily) is the recommended
dosage for the prevention of cognitive decline and memory support (3,
24). A treatment period of 14 days of ginkgo biloba was chosen to reach
steady state and to assess potential effects on metabolizing enzymes or
drug transporters. Raltegravir (Isentress; Merck Sharp &Dohme Limited,
Hoddesdon, United Kingdom) was administered as a single dose of 400
mg on an empty stomach, followed by a standardized breakfast 2 h after
intake. The breakfast consisted of a glass of milk and two slices of wheat
bread with cheese and cervelat.
Pharmacokinetic sampling and safety assessments. Blood samples
for assessment of the pharmacokinetic parameters of raltegravir were col-
lected during a 12-hour period at 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10,
and 12 h after intake of a single dose of 400 mg of raltegravir on days 15
and 36. Blood samples were collected in heparinized tubes and centri-
fuged for 10 min at 2,930 g at 20°C. Plasma was transferred to polypro-
pylene tubes and stored at40°C until further bioanalysis. Blood samples
for serum biochemistry and hematology were taken on days 15 and 36, as
well as before and during ginkgo biloba treatment (days 1 and 8 of treat-
ment). Subjects were asked about the presence of adverse events at each
visit day. Screening for drugs of abuse in urine was performed on days 15
and 36; blood glucose testing and urinalysis were carried out on day 36.
Pregnancy was checked by performing a human chorionic gonadotropin
(hCG) blood test on all female subjects on days 15 and 36.
Compliance. All intake of medication at the clinical trial unit was
supervised and recorded by the study personnel. Intake of ginkgo biloba
tablets at home was monitored by the use of microelectronic monitoring
system (MEMS) caps (Aardex Ltd., Zug, Switzerland), which record the
opening of the medication bottle. In addition, ginkgo biloba tablets were
counted on each visit day during ginkgo biloba treatment to assess adher-
ence. Subjects were asked to write down the exact times of intake in a
booklet.
Bioanalysis of raltegravir in plasma. The concentrations of raltegravir
in plasma were analyzed by use of a validated reversed-phase high-pressure
liquid chromatography (HPLC)methodwithfluorescencedetection. Sample
preparation consistedof a liquid-liquid extractionby adding 500l of acetate
buffer (pH 4.0; 0.2M), 5 ml of hexane/dichloromethane (1:1 [vol/vol]), and
50l of internal standard (lormetazepam inmethanol-water [1:1 {vol/vol}])
to 500 l of plasma. The samples were mixed on a vortex mixer for 5 min,
followedbycentrifugationat11,500g for5min.After freezingat40°Cfor
5min, the organic supernatant was decanted and evaporated at 37°C under a
stream of nitrogen gas. The residue was reconstituted in 200 l of eluent
(acetonitrile-phosphatebuffer, pH4.8; 20mM;35:65 [vol/vol]). Fortymicro-
liters of the reconstituted solutionwas injected onto a SymmetryShieldRP18
column (3.5m; 100 by 4.6mm). The flow rate was set at 1.5ml/min. Ralte-
gravir was detected by the use of a fluorescence detector (excitation, 240 nm;
emission, 412 nm). The lower limit of quantification was 0.014 mg/liter. The
linear calibration ranges in plasma were from 0.014 to 10 mg/liter. The vali-
dation results displayed accuracies of the quality control samples of 100%,
102%, and 107% at plasma concentrations of 0.060, 0.400, and 4.00mg/liter.
At the same concentrations, the precision values (within-day coefficients of
variation [CV]) were 3.7%, 1.8%, and 0%, respectively. The raltegravir assay
was performed at the laboratory of the Pharmacy of Radboud University
Nijmegen Medical Centre (Nijmegen, The Netherlands) and was externally
validated through the International InterlaboratoryQualityControlProgram
forMeasurement of Antiretroviral Drugs in Plasma (5).
Pharmacokinetic analysis. Pharmacokinetic parameters for raltegra-
vir were calculated by noncompartmental methods using the WinNonlin
software package (version 5.2; Pharsight, Mountain View, CA) and the
linear log trapezoidal rule. Based on the individual plasma concentration-
time data, the following pharmacokinetic parameters of raltegravir were
determined: the area under the plasma concentration-time curve from
dosing to infinity (AUC0-) (in mg · h/liter), the area under the plasma
concentration-time curve from 0 to 12 h after intake (AUC0-12) (in mg ·
h/liter), the maximum plasma concentration of the drug (Cmax) (in mg/
liter), the time to reach Cmax (Tmax) (in h), the apparent volume of distri-
bution (V/F) (in liters), the apparent oral clearance (CL/F) (in liters/h),
and the apparent elimination half-life (T1/2) (in h).
Sample size and statistical analysis. For the identification of a clini-
cally relevant drug interaction, the bioequivalence approach was used, as
described previously (25). The main pharmacokinetic parameter to be
evaluated in this respect is the exposure to raltegravir, expressed as the
AUC. Sample size calculation was performed using the method for two-
period designs of Diletti et al. (7) The required sample size was calculated
(power of 80%) assuming no difference in the AUC of raltegravir with or
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without ginkgo biloba and an estimated intrasubject coefficient of varia-
tion of the log-transformed AUC values for raltegravir of 20%. The re-
quired number of participants was 16. Taking dropouts into account, a
total of 18 subjects were included. Geometric mean ratios (GMRs) with
90% confidence intervals (CI) were calculated for AUC0-, AUC0-12 h,
Cmax, and T1/2 after log transformation of within-subject ratios of ralte-
gravir combined with ginkgo biloba versus raltegravir alone. GMRs with
90%CI falling entirely within the range of 0.80 to 1.25 were considered to
indicate no significant interaction. Statistical and descriptive analyses
were carried out using SPSS for Windows, version 16.0.1 (SPSS, Chicago,
IL), and Microsoft Office Excel 2007.
RESULTS
Baseline characteristics. A total of 18 subjects (9 male and 9 fe-
male, all Caucasian) were enrolled in the study and received treat-
ment. The mean (range) age, body weight, and body mass index
were 38 (22 to 55) years, 72 (52 to 93) kg, and 23 (19 to 28) kg/m2,
respectively. The subjects were in good general health, according
to medical histories, physical examinations, vital signs, and labo-
ratory data. All included subjects completed the trial and were
available for statistical evaluation.
Compliance. The compliance with the ginkgo biloba treat-
ment of all 18 subjects was good, as indicated by their statements
about the intake of the drug doses as noted in the booklets, the
number of ginkgo biloba tablets counted on each visit day, and the
MEMS caps (data not shown). Only two subjects admitted to hav-
ing missed one ginkgo biloba dose.
Pharmacokinetics. The pharmacokinetic parameters and the
plasma concentration versus time curves of raltegravir in the
presence and absence of steady-state ginkgo biloba are shown in
Table 1 and Fig. 1. Ginkgo biloba increased the maximum plasma
concentration (Cmax) and the area under the plasma concentra-
TABLE 1 Comparison of single-dose pharmacokinetic parameters of raltegravir with or without coadministerion of multiple doses of ginkgo biloba
in healthy volunteers
Pharmacokinetic parameter
Raltegravir alone Raltegravir ginkgo biloba
Raltegravir ginkgo
biloba/raltegravir alone
Geometric mean 95% CI Geometric mean 95% CI GMR 90% CI
AUC0- (mg · h/liter) 6.35
b 4.39–9.18 7.44 5.10–10.9 1.21b 0.93–1.58
AUC0-12 (mg · h/liter) 5.93 4.21–8.34 7.33 5.01–10.7 1.24 0.97–1.58
Cmax (mg/liter) 2.08 1.39–3.12 3.01 2.00–4.52 1.44 1.03–2.02
Tmax
a (h) 2.00 1.13–3.00 2.00 1.50–2.00
CL/F (liters/h) 63.0b 43.6–91.1 53.8 36.8–78.5
V/F (liters) 288b 193–429 220 148–325
T1/2 (h) 3.17
b 2.61–3.86 2.83 2.42–3.32 0.93b 0.73–1.17
a For Tmax, the median and interquartile range are reported.
b Two subjects were excluded because the T1/2 could not be determined.
FIG 1 Geometricmean plasma concentrations following a single dose of 400mg of raltegravir in the presence and absence of steady-state ginkgo biloba (semilog
scale on the inset).
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tion-time curve from dosing to infinity (AUC0-) of raltegravir.
The apparent elimination half-life of raltegravir did not appear to
be influenced by ginkgo biloba. The median time to reach Cmax of
raltegravir was 2.0 h irrespective of ginkgo biloba treatment. For
raltegravir coadministered with ginkgo biloba relative to raltegra-
vir alone, the GMRs (90% confidence intervals) were 1.21 (0.93 to
1.58) for AUC0-, 1.44 (1.03 to 2.02) for Cmax, and 0.93 (0.73 to
1.17) for T1/2 (Table 1). Two subjects were excluded from the
calculation of theGMRsofAUC0- andT1/2 because theT1/2 could
not be determined in these subjects. Figure 2 shows the individual-
subject changes in the Cmax and AUC0- of raltegravir alone and
coadministered with ginkgo biloba. Although a small majority of
the subjects showed an increase in the Cmax upon coadministra-
tion, considerable variation in the amount and direction of the
effect was seen, as well as variation between individuals. This also
applies to the observed individual changes in the AUC0-. The
FIG 2 Individual changes in the maximum plasma concentration (top) and the area under the concentration-time curve (bottom) of raltegravir alone versus
raltegravir coadministered with ginkgo biloba. (Two subjects were excluded because the T1/2 and AUC0- could not be determined.)
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coefficients of variation of the AUC0- values of raltegravir alone
and raltegravir with ginkgo biloba were 66% and 51%, respec-
tively.
Adverse events and safety assessments.The studymedication
was generally well tolerated, and no serious adverse events were
reported. There were no discontinuations due to adverse events,
and all subjects completed the trial. Sixteen subjects reported a
total of 32 adverse events. Five (16%) adverse events were consid-
ered possibly drug related (all were classified as grade I). Diarrhea
was reported by two subjects during ginkgo biloba treatment, and
one subject reported a transient headache, which was possibly
related to raltegravir and/or ginkgo biloba. One subject developed
a grade I triglyceride elevation after administration of raltegravir,
which returned to normal within 7 days. One subject had a mild
elevated gamma-glutamyltransferase (-GT), which remained el-
evated during the study.
DISCUSSION
Herb-drug interactions are an important consideration in HIV-
infected patients because herbs are frequently used, often not re-
ported, and a potential cause of drug failure. A popular herbal
product amongHIV-infected individuals is ginkgo biloba extract,
despite a lack of evidence for effectiveness or safety within this
special patient group. Because human and preclinical data were
inconclusive with regard to ginkgo biloba’s potential to modulate
UGT and P-gp activity, a drug interaction studywith raltegravir in
healthy volunteers was carried out.
Steady-state ginkgo biloba increased the mean exposure to
raltegravir (AUC0-) by 21% and the Cmax by 44%. However, the
large 90% confidence interval for the GMRs partly overlaps the
predefined range of 0.80 to 1.25 in the bioequivalence approach
and reflects the variability in the individual changes in the AUC0-
and Cmax of raltegravir (25). Based on our findings, raltegravir
exposure after a single dosewas not clinically significantly reduced
by concomitant use of ginkgo biloba extract at steady state, mak-
ing it less likely that ginkgo biloba is a UGT inducer, as suggested
by in vitro research (16). The observed mean increase in the Cmax
by concomitant use of ginkgo biloba is more likely to be caused by
a change in oral bioavailability than by inhibition of the metabo-
lism of raltegravir, because the apparent elimination half-life of
raltegravir remained unaffected. The slight increase in the ralte-
gravir AUC0-when combinedwith ginkgo biloba is largely due to
the observed increase in the Cmax (Fig. 1). The difference in the
Cmax of raltegravir alone versus raltegravir with ginkgo biloba
within subjects could be (partly) due to the normal intrasubject
variability in raltegravir pharmacokinetics instead of an effect
caused by ginkgo biloba. It is known that raltegravir pharmaco-
kinetics exhibits considerable intra- and intersubject variability
(2, 4). A possible explanation for the increase in the Cmax and
bioavailability of raltegravir when combined with ginkgo biloba
could be the inhibition of P-gp by ginkgo biloba. In vitro charac-
terization of raltegravir transport by drug transporters indicates
that raltegravir is a weak P-gp substrate (20). P-gp is an active
ATP-dependent efflux pump and is encoded by the ABCB1 gene.
Effluxmechanisms, such as P-gp, are responsible for transporting
a broad range of compounds out of the intestinal epithelial cells
back into the intestinal lumen and play an important role in oral
drug absorption. The effect of chronic use of ginkgo biloba extract
on the pharmacokinetics of the P-gp substrate talinolol was stud-
ied in healthy volunteers. The observed increase in the Cmax by
33% and in the AUC by 21%without any significant alterations in
the Tmax and T1/2 of talinolol supports our hypothesis (9, 10). The
variation in change of the oral bioavailability of raltegravir and
subsequent Cmax values could be a reflection of individual varia-
tion in the inhibitory potential of P-gp by ginkgo biloba. The
expression and transport activities of P-gp may differ between
individuals due to genetic variation in the highly polymorphic
ABCB1 gene (11, 15). Therefore, the extent of the inhibition of
P-gpmay vary accordingly. Although inhibition of P-gp-mediated
efflux of raltegravir by ginkgo biloba is an interesting hypothesis,
onemust be cautious in translating findings obtained from in vitro
experiments directly to the clinical setting. Raltegravir transport
by P-gp is not yet confirmed in human studies. There are currently
no clinical data indicating that the pharmacokinetic profile of
raltegravir may be affected by selective P-gp inducers or inhibi-
tors.
It is well known that the pharmacokinetics of raltegravir dis-
plays large intersubject variability, which was observed in our
study, as well (CV inAUC0-, 66%) (2, 4). Contributing factors, in
general, are differences in absorption due to food intake or pH
effects, genetic polymorphisms associated with altered UGT1A1
activity, and potential drug interactions. In this study, raltegravir
was administered in a fasted state to minimize intersubject vari-
ability. Nevertheless, differences in gastric pH and therefore ab-
sorption of raltegravir probably led to variability in pharmaco-
kinetic parameters between subjects, and maybe within subjects,
as well. Individuals with decreased UGT1A1 expression caused
by UGT1A1*28 polymorphism (approximately 7 to 19% of the
Caucasian population is homozygous for UGT1A1*28) are
known to have moderately elevated plasma levels of raltegravir.
However, this increase in the plasma level is not considered to be
of clinical importance (14, 27). Pharmacogenetic testing was not
performed in our study, and UGT1A1*28 polymorphism might
have contributed to the intersubject variability, as well. In two
subjects, the elimination half-life of raltegravir could not be deter-
mined because of secondary peaks in the plasma concentration-
time curve. These secondary peaks are frequently observed in
pharmacokinetic studies of raltegravir and can be attributed to
either delayed absorption or enterohepatic circulation, which is
not uncommon for UGT substrates (4, 6). The pharmacokinetic
parameters observed in this study were compared with data
from Wenning et al., as these healthy subjects (all with the
UGT1A1*1/*1 genotype) were exposed to similar study condi-
tions, i.e., a single intake of a 400-mg raltegravir tablet on an
empty stomach (27). No major differences between our data and
these historical controls could be observed.
The combined use of chronic ginkgo biloba and a single dose of
raltegravir was well tolerated. No serious events were reported
during the trial. The reported adverse events related to the study
medication were mild and transient. In clinical practice, raltegra-
vir is well tolerated, with no dose-related toxicities indentified so
far. Given that there have been no acute safety findings associated
with peak raltegravir concentrations, the somewhat higher Cmax
values for raltegravir when coadministered with ginkgo biloba
compared with intake of raltegravir alone are not expected to lead
to any meaningful clinically significant safety concerns.
Our study was undertaken in healthy volunteers, limiting our
interpretation in HIV-infected individuals with concomitant
medication and comorbidity. Because of the inconsistencies and
controversies in the literature regarding the exact action of ginkgo
Blonk et al.















biloba extract on metabolizing enzymes or drug transporters and
the variation in effects seen in this study, it is not possible to draw
any definite conclusions. However, the study does provide data to
support the idea that raltegravir can be used safely for the man-
agement ofHIV infectionwhen taken in combinationwith ginkgo
biloba.Nodecrease in theAUC0- of raltegravir was observed, and
the increases in themaximumplasma concentrations are not con-
sidered to be of clinical importance, due to the normal intersub-
ject variability of raltegravir pharmacokinetics and the good safety
profile of raltegravir.
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